Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors
摘要:
The synthesis, SAR, binding affinities and pharmacokinetic profiles are described for a series of cyclohexane- based prolylcarboxypeptidase (PrCP) inhibitors discovered by high throughput screening. Compounds show high levels of ex vivo target engagement in mouse plasma 20 h post oral dose. (C) 2013 Elsevier Ltd. All rights reserved.
[EN] DOPAMINE D2 RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR D2 DE LA DOPAMINE
申请人:BROAD INST INC
公开号:WO2016100823A1
公开(公告)日:2016-06-23
The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.
In particular, the present invention is concerned with compounds of the general formula (I)
wherein X, Y and R
1
to R
10
are as described herein. The compounds are V1a receptor antagonists. The invention also relates to the manufacture of compounds of formula I, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.
4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
申请人:Amberg Wilhelm
公开号:US20100222346A1
公开(公告)日:2010-09-02
The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.
4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
申请人:Amberg Wilhelm
公开号:US08420670B2
公开(公告)日:2013-04-16
The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.
@ A series of novel N-pyridinyl- and pyrinidinyl sulfonamides are useful as fungicides and herbicides. These compounds are particularly useful for the protection of plants from phytopathogens.